SCHEMBL2407459

SCHEMBL2407459

CC(C)N(C(C)C)N(N(C(C)C)C(C)C)P(O)OCCC#N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1069685 0.84 NLRP3 (0.31)
SCHEMBL1856537 0.83
SCHEMBL7858703 0.81 TSHR (0.30)
SCHEMBL252367 0.81 TSHR (0.30)
SCHEMBL7262903 0.81 TSHR (0.30)
Hydrochloric Acid SCHEMBL25380883 0.80
SCHEMBL8139931 0.80
SCHEMBL23384350 0.76 TSHR (0.31)
SCHEMBL9662674 0.75 CASP1 (0.32)
SCHEMBL5063697 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853132-B2 Directed synthesis of oligophosphoramidate stereoisomers ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2014-10-07 US disclosed
US-20140045719-A1 DIRECTED SYNTHESIS OF OLIGOPHOSPHORAMIDATE STEREOISOMERS ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2014-02-13 US disclosed
US-8569515-B2 Directed synthesis of oligophosphoramidate stereoisomers ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2013-10-29 US disclosed
EP-2370450-A1 DIRECTED SYNTHESIS OF OLIGOPHOSPHORAMIDATE STEREOISOMERS Roche Diagnostics GmbH (DE) 2011-10-05 EP disclosed
US-20110212861-A1 DIRECTED SYNTHESIS OF OLIGOPHOSPHORAMIDATE STEREOISOMERS ROCHE DIAGNOSTICS GMBH (DE) 2011-09-01 US disclosed
WO-2010060599-A1 DIRECTED SYNTHESIS OF OLIGOPHOSPHORAMIDATE STEREOISOMERS ROCHE DIAGNOSTICS GMBH (DE) 2010-06-03 WO disclosed
US-20090069263-A1 4'-THIOARABINONUCLEOTIDE-CONTAINING OLIGONUCLEOTIDES, COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USES THEREOF THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2009-03-12 US disclosed
WO-2008141799-A1 OLIGOPHOSPHORAMIDATES ROCHE DIAGNOSTICS GMBH (DE) 2008-11-27 WO disclosed
US-7427675-B2 Compounds and methods for the characterization of oligonucleotides ISIS PHARMACEUTICALS, INC. (US) 2008-09-23 US disclosed
US-7427678-B2 Method for immobilizing oligonucleotides employing the cycloaddition bioconjugation method SIGMA-ALDRICH CO. (US) 2008-09-23 US disclosed
EP-1180113-A4 OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY ISIS PHARMACEUTICALS INC (US) 2002-09-18 EP disclosed
US-6369209-B1 AFFINITY AND NUCLEASE RESISTANCE WHILE CONCURRENTLY SERVING AS SUBSTRATES FOR RNASE H WHEN BOUND TO A TARGET RNA STRAND ISIS PHARMACEUTICALS, INC. 2002-04-09 US disclosed
US-6365379-B1 SELECTIVELY CLEAVING SINGLE STRANDED RNA BY CONTACTING WITH DIMERIZED ZINC FINGER PEPTIDE OF DEFINED AMINO ACID SEQUENCE IN ABSENSE OF ZINC ISIS PHARMACEUTICALS, INC. 2002-04-02 US disclosed
EP-1180113-A1 OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY ISIS PHARMACEUTICALS, INC. (US) 2002-02-20 EP disclosed
WO-2001084234-A1 METHOD FOR IMMOBILIZING OLIGONUCLEOTIDES EMPLOYING THE CYCLOADDITION BIOCONJUGATION METHOD PROLIGO LLC (US) 2001-11-08 WO disclosed
EP-1121455-A1 ZINC FINGER PEPTIDE CLEAVAGE OF NUCLEIC ACIDS ISIS PHARMACEUTICALS, INC. (US) 2001-08-08 EP disclosed
US-6271358-B1 FOR INHIBITING SPECIFIC GENE EXPRESSION; HAVING ENHANCED HYBRID BINDING AFFINITY AND/OR INCREASED NUCLEASE RESISTANCE ISIS PHARMACEUTICALS, INC. 2001-08-07 US disclosed
WO-2000066609-A1 OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY ISIS PHARMACEUTICALS, INC. (US) 2000-11-09 WO disclosed
WO-2000020622-A9 ZINC FINGER PEPTIDE CLEAVAGE OF NUCLEIC ACIDS ISIS PHARMACEUTICALS INC (US) 2000-09-08 WO disclosed
WO-2000020622-A1 ZINC FINGER PEPTIDE CLEAVAGE OF NUCLEIC ACIDS ISIS PHARMACEUTICALS, INC. (US) 2000-04-13 WO disclosed